ArticleNutrients2025
Impact of Phosphate Variability in Patients Undergoing Hemodialysis.
Article in Nutrients, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundThere are few studies investigating the relationship between phosphate level variability and clinical prognosis in hemodialysis (HD) patients. This study aimed to evaluate the impact of phosphate variability on clinical outcomes in maintenance HD patients using a population-based cohort.
methodsWe analyzed data from 55,225 patients who underwent periodic HD quality assessments and claims review. Phosphate variability was assessed using the residual standard deviation (SD) from a within-subject linear regression model based on six phosphate measurements per patient. Participants were categorized into quartiles based on phosphate variability. A balanced cohort was created using generalized boosted models for relevant covariates.
resultsAfter weighting, the residual phosphate SDs were 0.35 ± 0.00 mg/dL (Q1), 0.57 ± 0.00 mg/dL (Q2), 0.79 ± 0.00 mg/dL (Q3), and 1.22 ± 0.00 mg/dL (Q4). The mean follow-up duration across all quartiles was 50 ± 0.2 months. Multivariable Cox regression analysis revealed that patients in the Q4 group had a significantly higher hazard ratio (HR) for all-cause mortality and dementia compared with the Q1 group. Among all quartiles, Q1 showed the lowest HR for dementia. These trends were consistent with those observed in spline curve analyses. However, no significant association was found between phosphate variability and cardiovascular events.
conclusionsHigh phosphate variability was associated with increased risk of all-cause mortality and dementia in maintenance HD patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.